2X1:ETR
Abivax SA
78,05 €
arrow_downward
-1,58%(-1,25) 1G
5 nov, 17:35:45 GMT+1 · EUR
search
Tutti i simboli
| Simbolo | Prezzo | Cambio | % di cambio |
|---|
insights_autoGenerazione degli insight principali per 2X1 in corso…
Apertura
81,30 €
Massimo
82,45 €
Minimo
78,05 €
Cap. mercato
7,03 Mld
Vol. medio
1,00K
Volume
656,00
Max 52 sett.
137,40 €
Min 52 sett.
60,85 €
Utili per azione
-5,20 €
N. di dipendenti
98
Apertura
81,30 €
Massimo
82,45 €
Minimo
78,05 €
Cap. mercato
7,03 Mld
Vol. medio
1,00K
Volume
656,00
Max 52 sett.
137,40 €
Min 52 sett.
60,85 €
Utili per azione
-5,20 €
N. di dipendenti
98
Articoli giornalistici
Da fonti web e partner giornalistici
www.debelegger.nl
·
1 giorno fa
Abivax SA American Depositary Shares (ABVX) Stock Price, Chart & Analysis
Idéal Investisseur
·
3 giorni fa
Abivax shares at the bottom of the SBF 120, down 27% over the quarter
Profilo
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Informazioni su Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Dipendenti98
Data di fondazione4 dic 2013
Sede-
Settore-
Industry-
Sito webabivax.com